Although psychotherapy is available via the Veterans Health Administration, most veterans diagnosed with posttraumatic stress disorder (PTSD) receive pharmacotherapy. This study evaluated longitudinal prescription practice trends for veterans with PTSD.
The pandemic has clearly placed a tremendous strain on health care workers, but how has it affected their ability to function in their daily lives and the likelihood of burnout? This large survey from a New York hospital provides some answers.
Posttraumatic stress disorder and prolonged grief disorder (PGD) both arise following major life stressors. This study examined the presence and response to treatment of posttraumatic stress symptoms in bereaved adults with a primary diagnosis of PGD.
In this letter, Dr Hernandez and colleagues reply to a letter from Brigido et al that comments on their recent article on the impact of comorbid posttraumatic stress disorder on outcomes of treatment with repetitive transcranial magnetic stimulation in depressed veterans.
This letter to the editor builds on the findings of a recent article by Hernandez and colleagues on the impact of comorbid posttraumatic stress disorder on outcomes of treatment with repetitive transcranial magnetic stimulation in depressed veterans.
Optimal intervention for patients experiencing PTSD often includes prolonged follow-up that applies both talk and drug therapies in a supportive environment. This narrative review describes psychotherapeutic and pharmacologic approaches to treat PTSD.
Prolonged exposure is a gold-standard trauma therapy, but trials in military populations show not all patients experience symptom improvement. This 10-week pilot looked at the feasibility of combining ketamine and prolonged exposure for better outcomes.
Current pharmacologic treatments for posttraumatic stress disorder (PTSD) have shown limited efficacy. This study investigated the efficacy of the glutamatergic modulator riluzole for combat-related PTSD symptoms resistant to SSRIs or SNRIs.
Open trials and small controlled trials suggest mirtazapine is beneficial in treating posttraumatic stress disorder (PTSD). This randomized controlled trial study sought to determine the efficacy of mirtazapine monotherapy for PTSD.
This retrospective study explored whether 5 medications for PTSD with efficacy in meta-analyses of randomized controlled trials—fluoxetine, paroxetine, sertraline, topiramate, and venlafaxine—are also effective in routine clinical practice.
Research has revealed the feasibility of positive psychiatry in youth. This study investigated the impact of reminder-focused positive psychiatry on PTSD and ADHD symptoms, neuroinflammation, vascular function, well-being, and posttraumatic growth.
Baclofen, a French Exception, Seriously Harms Alcohol Use Disorder Patients Without Benefit
To the Editor: Dr Andrade’s analysis of the Bacloville trial in a recent Clinical and Practical Psychopharmacology column, in which he concluded that “individualized treatment with high-dose baclofen (30-300 mg/d) may be a useful second-line approach in heavy drinkers” and that “baclofen may be particularly useful in patients with liver disease,” deserves comment.1
First, Andrade failed to recall that the first pivotal trial of baclofen, ALPADIR (NCT01738282; 320 patients, as with Bacloville), was negative (see Braillon et al2).
Second, Dr Andrade should have warned readers that Bacloville’s results are most questionable, lacking robustness. Although he cited us,3 he overlooked the evidence we provided indicating that the Bacloville article4 was published without acknowledging major changes to the initial protocol, affecting the primary outcome. Coincidentally (although as skeptics, we do not believe in coincidence), the initial statistical team was changed when data were sold to the French pharmaceutical company applying for the marketing authorization in France. As Ronald H. Coase warned, “If you torture the data long enough, it will confess.”